



UniversitätsKlinikum Heidelberg

# How will new high sensitive troponins affect the criteria?


***Hugo A Katus MD***

*Abteilung Innere Medizin III*

*Kardiologie, Angiologie, Pulmologie*

*Universitätsklinikum Heidelberg*

# Even more sensitive: The new Troponin T assay hs



# Universal Definition of Myocardial Infarction

## Criteria of Myocardial Infarction

### Myocardial necrosis:

Detection of **rise and/or fall** of cardiac biomarker (preferably troponins) with at least one value above the 99th percentile of the upper reference limit


With evidence of myocardial ischemia with at least one of the following:

- Symptoms of ischemia
- New ST-T changes or LBBB
- Development of new Q-waves
- Imaging evidence of new loss of viable myocardium
- or new regional wall motion abnormality

# Sub-Classification of AMI

- Type 1** Spontaneous myocardial infarction related to ischemia due to a primary coronary event such as plaque erosion or rupture, fissuring or dissection
- Type 2** Myocardial infarction secondary to ischemia due to imbalance between oxygen demand and supply e.g. coronary spasm, anemia, or hypotension
- Type 3** Sudden cardiac death with symptoms of ischemia, accompanied by new ST elevation or LBBB, or verified coronary thrombus by angiography or autopsy, but death occurring before blood samples could be obtained
- Type 4a** Myocardial infarction associated with PCI
- Type 4b** Myocardial infarction associated with verified stent thrombosis
- Type 5** Myocardial infarction associated with CABG

# Applying the Universal Definition of MI: What Has Happened with the Diagnosis of Unstable Angina?



# Diagnostic performance of serial blood sampling using 99th percentile in evolving MI

Higher delta improves specificity

	Sens %	Spec %	PPV	NPV
Baseline sample >99th	62	77	69	71
FU sample 3hours >99th	100	77	65	100
FU sample >99th + 20%delta	85	57	79	67
FU sample >99th + 117%delta	69	100	100	88

# Predictors of Death at 3 years FU

<b>N=1530</b>	<b>HR</b>	<b>95%CI</b>	<b>p-value</b>
<b>TnT<sub>hs</sub> ≥14 pg/ml</b>	<b>7.591</b>	<b>1.006-57.3</b>	<b>0.049</b>
<b>Age ≥ 75 years</b>	<b>2.753</b>	<b>1.448-5.233</b>	<b>0.002</b>
<b>GFR &lt;60 ml/min/1.73m<sup>2</sup></b>	<b>2.318</b>	<b>1.364-3.938</b>	<b>0.002</b>
<b>TIMI Risk Score by Tertiles</b>	<b>1.193</b>	<b>0.876-1.626</b>	<b>0.263</b>
<b>NT-proBNP &gt; 2399 pg/ml (ROC-optimized)</b>	<b>5.698</b>	<b>3.252-9.983</b>	<b>&lt;0.001</b>
<b>cTnT ≥ 0.03 µg/l</b>	<b>1.752</b>	<b>0.778-3.947</b>	<b>0.176</b>

# Unstable angina and treatment options

Hazard Ratios and Rates of Primary End Point in Predefined Subgroups of Study Patients

Characteristic	Hazard Ratio (95% CI)	Total Patients	KM % at Month 12		HR (95% CI)	P value (Interaction)
			TL	CI		
<b>Overall Treatment Effect</b>						
Primary Endpoint		18624	9.8	11.7	0.84 (0.77, 0.92)	
<b>New ST elevation/LBBB at rand.</b>						
No		11074	10.1	12.3	0.83 (0.74, 0.93)	0.68
Yes		7544	9.4	10.8	0.87 (0.75, 1.01)	
<b>First Troponin I</b>						
Positive		15089	10.3	12.3	0.85 (0.77, 0.94)	0.29
Negative		2968	7.0	7.0	1.00 (0.75, 1.32)	
<b>Time from Index Event to First IP</b>						
<12 hours		9556	8.2	10.4	0.79 (0.69, 0.90)	0.17
≥12 hours		8854	11.4	12.9	0.90 (0.79, 1.01)	
<b>Planned Treatment Approach</b>						
Invasive		13408	8.9	10.6	0.84 (0.75, 0.94)	0.88
Medically managed		5216	12.0	14.3	0.85 (0.73, 1.00)	
<b>TIMI Risk Score: UA/NSTEMI</b>						
0-2		730	4.2	4.1	1.11 (0.53, 2.31)	0.27
3-4		5488	8.2	10.9	0.77 (0.64, 0.92)	
5-7		4849	14.4	15.6	0.92 (0.79, 1.07)	
<b>TIMI Risk Score: STEMI</b>						
0-2		3889	4.7	6.2	0.76 (0.58, 1.01)	0.32
≥3		3137	13.1	15.2	0.86 (0.71, 1.04)	


# Sub-Classification of AMI

- Type 1 Spontaneous myocardial infarction related to ischemia due to a primary coronary event such as plaque erosion or rupture, fissuring or dissection
- Type 2 Myocardial infarction secondary to ischemia due to imbalance between oxygen demand and supply e.g. coronary spasm, anemia, or hypotension**
- Type 3 Sudden cardiac death with symptoms of ischemia, accompanied by new ST elevation or LBBB, or verified coronary thrombus by angiography or autopsy, but death occurring before blood samples could be obtained
- Type 4a Myocardial infarction associated with PCI
- Type 4b Myocardial infarction associated with verified stent thrombosis
- Type 5 Myocardial infarction associated with CABG

# Diagnoses in Chest Pain Patients

**TnTbs negative  
non-ACS**  
2645 pts  
(75.6%)

**CPU Registry Heidelberg (n=3,327)  
8.6.2009 – 30.11.2009 (6-months)**



**TnTbs positive  
non-ACS**  
471 pts  
(13.5%)

**STEMI**  
62 pts  
(1.8%)


**NSTEMI**  
149 pts  
(4.3%)

**UA**  
173 pts  
(4.9%)

**Median number of TnTbs measurements 3 (IQR 3-5, range 2-6)**


**20% of consecutive pts admitted to CPU TnTbs positive !!  
69% elevations are not due to clinical ACS !!**

# High Sensitive Troponin T is a Strong Predictor of Outcomes in Patients with Chronic Heart Failure - A Study from the Val-HeFT Trial



# Acute Pulmonary Embolism

## Probability of Long-Term Survival





# hsTnT and Plaque Morphology in Stable Coronary Artery Disease

Normal CA

Calcified CA-PI

Non Calcified CA-PI

Complex CA-PI



# CT angiography and biomarkers in subjects without ACS as a function of hsTnT

Characteristic	hsTnT $\geq$ 13 pg/mL (N=38)	hsTnT <13 pg/mL (N=302)	P
<b><i>Coronary CT angiography</i></b>			
Segments with calcified plaque	4.4 ( $\pm$ 4.0)	1.5 ( $\pm$ 3.0)	<.001
Segments with non-calcified plaque	1.8 ( $\pm$ 3.0)	0.8 ( $\pm$ 2.0)	.05
Segments with mixed plaque	1.4 ( $\pm$ 2.5)	0.5 ( $\pm$ 1.4)	.04
Segments with plaque	4.8 ( $\pm$ 5.0)	1.7 ( $\pm$ 3.0)	.001
Segments with significant stenosis	0.4 ( $\pm$ 1.0)	0.06 ( $\pm$ 0.3)	.04
Vessels with significant stenosis	0.2 ( $\pm$ 0.5)	0.05 ( $\pm$ 0.3)	.09
Vessels with plaque	2 ( $\pm$ 1.8)	0.9 ( $\pm$ 1.3)	.001
<b><i>Cardiac chamber size and function</i></b>			
Left atrial diastolic volume, mL	107 ( $\pm$ 33.0)	95 ( $\pm$ 24.0)	.02
Left atrial systolic volume, mL	69 ( $\pm$ 31.0)	55 (17.0)	.01
Left ventricular end diastolic volume, mL	122 ( $\pm$ 45.0)	117 ( $\pm$ 30.0)	.50
Left ventricular end systolic volume, mL	48 ( $\pm$ 41.0)	38 ( $\pm$ 16.0)	.20
Left ventricular mass	173 ( $\pm$ 60.0)	147 ( $\pm$ 39.0)	.01
Left ventricular ejection fraction, %	65 ( $\pm$ 14.0)	68 ( $\pm$ 9.0)	.30
Regional left ventricular dysfunction	8 (22%)	24 (8%)	.008
<b><i>Biomarkers besides TnT</i></b>			
NT-proBNP, pg/mL, median (interquartile range)	248 (92-492)	42 (23-86)	<.001
Cystatin-C, mg/L, median (interquartile range)	0.93 (0.75-1.07)	0.82 (0.73-0.92)	.05

# Sub-Classification of AMI

- Type 1** Spontaneous myocardial infarction related to ischemia due to a primary coronary event such as plaque erosion or rupture, fissuring or dissection
- Type 2** Myocardial infarction secondary to ischemia due to imbalance between oxygen demand and supply e.g. coronary spasm, anemia, or hypotension
- Type 3** Sudden cardiac death with symptoms of ischemia, accompanied by new ST elevation or LBBB, or verified coronary thrombus by angiography or autopsy, but death occurring before blood samples could be obtained


## **Type 4a Myocardial infarction associated with PCI**

- Type 4b** Myocardial infarction associated with verified stent thrombosis
- Type 5** Myocardial infarction associated with CABG


# Kaplan-Meier survival estimates for those with (TnT $\geq 0.03$ ) and without (TnT)

1,949 patients from the Mayo Clinic registry

All had normal CK-MB after the procedure  
 383 (19.6%) patients with elevated cTnT




cTnT < 0.03	1540	1398	979	553
cTnT $\geq 0.03$	376	335	235	131





cTnT < 0.03	1540	1362	946	536
cTnT $\geq 0.03$	376	326	226	126

# Cutoff concentrations for diagnosis of periprocedural MI



# Incidence and prognostic role of Universal Definition Type IV MI


**Meta-analysis 15 studies, 7578 patients**



Elevation of troponin after scheduled PCI: 28.7%  
 PCI-related MI by Universal definition: 14.5%.

Type IV MI: Death OR 17.25 (2.71–109.96), P = 0.003,  
 Re-PCI OR 10.86 (3.2–36.94), P < 0.001

# Type 4 MIs after Elective PCI ( $> 3 \times 99$ th percentile = 42 pg/ml)



# Prognostic significance of preprocedural cardiac troponin elevation among patients with stable CAD undergoing PCI: The EVENT Registry

	cTn Positive (n=142)	cTn Negative (n=2240)	<i>P</i>
Death or MI, n (%)	19 (13.4)	126 (5.6)	<0.001
Death, n (%)	1 (0.7)	0 (0.0)	0.060
MI, n (%)	19 (13.4)	126 (5.6)	<0.001
Urgent repeat PCI, n (%)	2 (1.4)	5 (0.2)	0.061
Urgent CABG, n (%)	1 (0.7)	6 (0.3)	0.35
Stent thrombosis, n (%)	0 (0.0)	5 (0.2)	1.00
Any angiographic complication, n (%) <sup>*</sup>	16 (7.5)	121 (4.0)	0.012

CABG indicates coronary artery bypass grafting.


\*Lesion-based analysis.

7592 consecutive patients  
142 (6.0%) cTnT + at baseline


# Sub-Classification of AMI

- Type 1** Spontaneous myocardial infarction related to ischemia due to a primary coronary event such as plaque erosion or rupture, fissuring or dissection
- Type 2** Myocardial infarction secondary to ischemia due to imbalance between oxygen demand and supply e.g. coronary spasm, anemia, or hypotension
- Type 3** Sudden cardiac death with symptoms of ischemia, accompanied by new ST elevation or LBBB, or verified coronary thrombus by angiography or autopsy, but death occurring before blood samples could be obtained
- Type 4a** Myocardial infarction associated with PCI
- Type 4b** Myocardial infarction associated with verified stent thrombosis
- Type 5** Myocardial infarction associated with CABG

# CTnT and Out-Come Following CABG-Surgery



# Cutoff concentrations for diagnosis of MI post CABG




# Magnitude of cTnT release after CABG postoperative complications

**Universal MI definition:  
Type V MI (Periprocedural MI)  
If cTn >5x99th percentile**

**= 0.07 ng/mL**

**2% new Q-waves or LBBB  
98.9% had a cTnT 0.03 ng/mL,  
97.5% had a cTnT 0.10 ng/mL**




# Impact of hsTn on AMI Diagnosis/ Criteria

- **Type 1: Many more patients rule in for AMI, prevalence of unstable angina will diminish but risk prediction will be improved**
- **Type 2 AMIs will remain a diagnostic challenge**
- **Type 4 AMI will be observed in 10-40% of elective PCIs. The prognostic impact of minor marker increases needs to be tested prospectively**
- **Type 5 AMI will need revision due to extra-ordinarily high rate of peri-operative AMI diagnoses and lack of prognostic information at low levels**




# Troponin Release: Type of Surgery




# Short- and long-term biological variation in hscTnT

Variable	Short-term (0-4 h)	Long-term (0-8 weeks)
Analytical variation		
$CV_{A, \%}$ *	53.5	98
Biological variation		
$CV_{I, \%}$	48.2	94
$CV_{G, \%}$	85.9	94
Index of Individuality	84.5	19.6
RCV, lognormal increase, %	84.6	315
Mean Delta Increase, %	58	103.4
Mean Delta Decrease, %	57.5	87


# Optimal delta change for prediction of evolving NSTEMI\*




# Maximal hsTnT within 6 hours for prediction of MI



# Early delta change in ACS versus TnT-positive non-ACS patients



# Diagnostic sensitivity of TnT hs compared to cTnT



p between cTnT adm and hsTnT adm (UAP/NSTEMI) < 0.0001


p between cTnT final and hsTnT final (UAP/NSTEMI) < 0.0001

p between cTnT adm and cTnT final (UAP/NSTEMI) = 0.0003


p between hsTnT adm and hsTnT final (UAP/NSTEMI) = 0.0008



# Distribution of new or recurrent MIs (n=1218) by the universal definition of MI clinical classification




# All-cause Death by TnThs 99th percentile




N=1530

# All-cause mortality at 3yrs follow up cTnThs tertiles by diagnosis

N=1530



# HsTnT and Outcomes in Heart Failure: The Valheft-Trial



# Case 4: A 78 year old female

## History:

- referred to our chest pain unit with dizziness, vomiting and nausea
- no typical cardiac chest pain
- discrete shortness of breath and decrease of performance
- known diseases: subtle renal failure (MDRD 50 ml/min/1.73m<sup>2</sup>)
- CVRF: hypertension, hypercholesterolemia
- medication: ASS 100mg 0-1-0, candesartan 16mg 1-0-1, hydrochlorothiazid 12,5mg 1-0-1, nebivolol 5mg ½-0-½, pravastatin 20mg 0-0-1, estrogen 0,6mg 1-0-0


## Physical examination:

- 67.0 kg, 1.70 cm, BMI 23 kg/m<sup>2</sup>,
- RR adm 130/60mmHg, HR adm 80/min, 36.1 °C
- Auscultation: Cor/Pulmo: unsuspecting

# Case 4: EKG

02.06.2008 18:56:08


Vent rate: 84 BPM  
PR int: 193 ms  
QRS dur: 94 ms  
QT/QTc: 363 / 405 ms  
P-R-T axes: -9 -39 36




# Case 4: Laboratory Results

	<b>admission</b>		<b>after 24h</b>		<b>(norm)</b>
• creatinine	1.75		1.44		(1.1-1.3) mg/dl
• urea	100		80		(-45) mg/dl
• glucose	158		111		(70-110) mg/dl
• Hb	11.0		10.2		(12-15) g/dl
• platelets	233		231		(150-440) /nl
• white blood cells	9.34		7.82		(4-10) /nl
• C-reactive protein	9.9		8.7		(-5) mg/dl
• cTnT	0.02	0.04	0.02		(-0,03) µg/l
• hsTnT	40	60	50	30	(-14) pg/ml
• CK	44		70		(-170) U/l
• NTproBNP	na				(-450) ng/l
• normal values for sodium, potassium, GOT, GPT, LDH					

# Case 4: Left Ventricular Angiography



# Case 4: Coronary Angiography



# Postoperative cTnT results as a function of outcome after CABG

